CagriSema
Also known as: Cagrilintide + Semaglutide, Cagri/Sema
A combination of a long-acting amylin analog with a GLP-1 agonist to enhance satiety and appetite suppression for weight loss.
Components
How it's combined
In clinical research, CagriSema (Novo Nordisk) pairs cagrilintide (amylin analog acting on hindbrain satiety) with semaglutide (GLP-1 agonist) for additive appetite reduction; it is the combination with published human trial data among amylin pairings. Once-weekly subcutaneous in trial settings. Investigational as a combination.
Related pages
- CagriSema (Cagrilintide + Semaglutide) · the drug's reference page
Available from vendors
PeptideQuestions is an independent research resource, not the seller. Links go to third-party vendors; products are sold strictly as research chemicals and are not intended for human consumption. We may earn a commission on purchases. Disclosure How we Recommend Vendors
Independent research resource
Not a seller — PeptideQuestions doesn't sell or ship products.
Research-use-only framing
Content is educational, not a dosing recommendation.
Vendor links clearly disclosed
Outbound links to third-party vendors are always labeled.